EIF2D

Summary

EIF2D (eukaryotic translation initiation factor 2D, HGNC:6583) is a protein-coding gene on chromosome 1q32.1, encoding Eukaryotic translation initiation factor 2D (P41214). Translation initiation factor that is able to deliver tRNA to the P-site of the eukaryotic ribosome in a GTP-independent manner.

This gene encodes a translation initiation factor involved in the recruitment and delivery of aminoacyl-tRNAs to the P-site of the eukaryotic ribosome in a GTP-independent manner. This gene was previously referred to as ligatin, but is now known to localize to the cytoplasm and localize and function with translation factors. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 1939 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 124 total
• MANE Select transcript: NM_006893

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6583
Approved symbol	EIF2D
Name	eukaryotic translation initiation factor 2D
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	LGTN
Ensembl gene	ENSG00000143486
Ensembl biotype	protein_coding
OMIM	613709
Entrez	1939

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 17 protein_coding, 3 retained_intron, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000271764, ENST00000367114, ENST00000437518, ENST00000461334, ENST00000468891, ENST00000472709, ENST00000474408, ENST00000484492, ENST00000613435, ENST00000617960, ENST00000620382, ENST00000910991, ENST00000910992, ENST00000910993, ENST00000910994, ENST00000910995, ENST00000910996, ENST00000937103, ENST00000937104, ENST00000955145, ENST00000955146, ENST00000955147, ENST00000955148, ENST00000955149, ENST00000955150

RefSeq mRNA: 2 — MANE Select: NM_006893 NM_001201478, NM_006893

CCDS: CCDS1465, CCDS55680

Canonical transcript exons

ENST00000271764 — 15 exons

Exon	Start	End
ENSE00000960344	206611184	206611374
ENSE00000960346	206608236	206608326
ENSE00000960348	206602951	206603204
ENSE00001896912	206591642	206591845
ENSE00002386259	206593619	206593793
ENSE00003485651	206600263	206600308
ENSE00003488490	206599463	206599612
ENSE00003534897	206599003	206599092
ENSE00003569325	206599733	206599836
ENSE00003615350	206597100	206597195
ENSE00003659159	206605400	206605507
ENSE00003669568	206602336	206602453
ENSE00003672107	206609376	206609459
ENSE00003731489	206595718	206595838
ENSE00003841977	206612287	206612465

Expression profiles

Bgee: expression breadth ubiquitous, 281 present calls, max score 95.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.3352 / max 62.0517, expressed in 1793 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
17076	14.2910	1790
17075	1.9806	1248
17077	0.0636	16

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ovary	UBERON:0002119	95.60	gold quality
body of uterus	UBERON:0009853	95.21	gold quality
right ovary	UBERON:0002118	94.94	gold quality
right uterine tube	UBERON:0001302	94.80	gold quality
gluteal muscle	UBERON:0002000	94.71	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.60	gold quality
parotid gland	UBERON:0001831	94.49	gold quality
body of pancreas	UBERON:0001150	94.44	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.35	gold quality
endocervix	UBERON:0000458	94.12	gold quality
lower esophagus muscularis layer	UBERON:0035833	93.95	gold quality
apex of heart	UBERON:0002098	93.94	gold quality
lower esophagus	UBERON:0013473	93.93	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	93.89	gold quality
tibial nerve	UBERON:0001323	93.88	gold quality
triceps brachii	UBERON:0001509	93.82	gold quality
ovary	UBERON:0000992	93.74	gold quality
ectocervix	UBERON:0012249	93.67	gold quality
left lobe of thyroid gland	UBERON:0001120	93.63	gold quality
body of stomach	UBERON:0001161	93.61	gold quality
gastrocnemius	UBERON:0001388	93.60	gold quality
saliva-secreting gland	UBERON:0001044	93.58	gold quality
muscle of leg	UBERON:0001383	93.58	gold quality
right lobe of thyroid gland	UBERON:0001119	93.55	gold quality
right coronary artery	UBERON:0001625	93.52	gold quality
popliteal artery	UBERON:0002250	93.51	gold quality
tibial artery	UBERON:0007610	93.51	gold quality
thyroid gland	UBERON:0002046	93.45	gold quality
minor salivary gland	UBERON:0001830	93.38	gold quality
rectum	UBERON:0001052	93.36	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.13

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ESR2

miRNA regulators (miRDB)

15 targeting EIF2D, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111

Literature-anchored findings (GeneRIF, showing 7)

• Data suggest that neither eIF2A nor eIF2D are involved in the translation of this Sindbis virus subgenomic mRNA (sgmRNA) bearing non-AUG codons (PMID:28240315)
• Reinitiation complexes involving initiation factors eIF2D, MCT-1, and DENR controls the translation of a large fraction of mammalian cellular mRNAs. (PMID:28732596)
• a novel uORF-based regulatory mechanism that is employed under conditions of hyperosmotic stress by at least two human mRNAs, coding for translation reinitiation/recycling factor eIF2D and E3 ubiquitin ligase MDM2. This novel mode of translational control selectively downregulates their expression and requires as few as one uORF. (PMID:30419262)
• this is the first report which confirms the presence of ligatin and fibulin-7 in human aqueous humor, quantified their differential expression, and indicated the possibility of their involvement in the maintenance of the trabecular meshwork structure in glaucoma progression. (PMID:30958601)
• We observed a positive correlation trend between EIF2D mRNA levels and years of schizophrenia (SZ) disease (p=0.0794; r=0.35). We found a trend of an increase in the expression levels of EIF2D (p=0.0634) in patients suffering from the disease more than 10years compared with the SZ patients from the other subgroup . (PMID:31078689)
• The enterovirus genome can be translated in an IRES-independent manner that requires the initiation factors eIF2A/eIF2D. (PMID:36689548)
• To initiate or not to initiate: A critical assessment of eIF2A, eIF2D, and MCT-1.DENR to deliver initiator tRNA to ribosomes. (PMID:38433101)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	eif2d	ENSDARG00000012929
mus_musculus	Eif2d	ENSMUSG00000026427
rattus_norvegicus	Eif2d	ENSRNOG00000004910
drosophila_melanogaster	eIF2D	FBGN0041588
caenorhabditis_elegans		WBGENE00016113

Protein

Protein identifiers

Eukaryotic translation initiation factor 2D — P41214 (reviewed: P41214)

Alternative names: Hepatocellular carcinoma-associated antigen 56, Ligatin

All UniProt accessions (5): P41214, A0A087WVB6, A0A087X1L6, A0A087X202, Q5SY38

UniProt curated annotations — full annotation on UniProt →

Function. Translation initiation factor that is able to deliver tRNA to the P-site of the eukaryotic ribosome in a GTP-independent manner. The binding of Met-tRNA(I) occurs after the AUG codon finds its position in the P-site of 40S ribosomes, the situation that takes place during initiation complex formation on some specific RNAs. Its activity in tRNA binding with 40S subunits does not require the presence of the aminoacyl moiety. Possesses the unique ability to deliver non-Met (elongator) tRNAs into the P-site of the 40S subunit. In addition to its role in initiation, can promote release of deacylated tRNA and mRNA from recycled 40S subunits following ABCE1-mediated dissociation of post-termination ribosomal complexes into subunits.

Subcellular location. Cytoplasm.

Similarity. Belongs to the eIF2D family.

Isoforms (2)

UniProt ID	Names	Canonical?
P41214-1	1	yes
P41214-2	2

RefSeq proteins (2): NP_001188407, NP_008824* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001950	SUI1	Domain
IPR002478	PUA	Domain
IPR003121	SWIB_MDM2_domain	Domain
IPR015947	PUA-like_sf	Homologous_superfamily
IPR036877	SUI1_dom_sf	Homologous_superfamily
IPR036885	SWIB_MDM2_dom_sf	Homologous_superfamily
IPR039757	EIF2D	Family
IPR039759	eIF2D_SUI1	Domain
IPR041366	Pre-PUA	Domain
IPR048247	eIF2D_N	Domain
IPR048248	PUA_eIF2d-like	Domain
IPR057429	WH_eIF2D	Domain
IPR058886	SWIB_eIF2D	Domain

Pfam: PF01253, PF17832, PF25304, PF26291, PF26292

UniProt features (41 total): strand 11, helix 11, modified residue 4, sequence conflict 4, domain 3, turn 2, compositionally biased region 2, chain 1, splice variant 1, sequence variant 1, region of interest 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
5W2F	X-RAY DIFFRACTION	1.4
5OA9	X-RAY DIFFRACTION	1.8
5OA3	ELECTRON MICROSCOPY	4.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P41214-F1	76.23	0.31

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 361, 1, 237, 254

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 186 (showing top): GOBP_CYTOPLASMIC_TRANSLATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_TRANSLATIONAL_INITIATION, GOMF_TRANSLATION_INITIATION_FACTOR_ACTIVITY, GOBP_TRANSLATION, NIKOLSKY_BREAST_CANCER_1Q32_AMPLICON, GOBP_FORMATION_OF_TRANSLATION_PREINITIATION_COMPLEX, GOBP_CYTOPLASMIC_TRANSLATIONAL_INITIATION, GOBP_PROTEIN_RNA_COMPLEX_ORGANIZATION, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GOBP_ORGANELLE_DISASSEMBLY, CASTELLANO_HRAS_AND_NRAS_TARGETS_UP, HATADA_METHYLATED_IN_LUNG_CANCER_UP, CHENG_RESPONSE_TO_NICKEL_ACETATE, GOBP_VIRAL_GENE_EXPRESSION

GO Biological Process (7): formation of translation preinitiation complex (GO:0001731), intracellular protein transport (GO:0006886), ribosome disassembly (GO:0032790), IRES-dependent viral translational initiation (GO:0075522), translation (GO:0006412), translational initiation (GO:0006413), protein-containing complex organization (GO:0043933)

GO Molecular Function (3): RNA binding (GO:0003723), translation initiation factor activity (GO:0003743), signaling receptor activity (GO:0038023)

GO Cellular Component (3): cytoplasm (GO:0005737), cytosol (GO:0005829), nuclear body (GO:0016604)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
translational initiation	2
cellular anatomical structure	2
cytoplasmic translational initiation	1
protein-RNA complex assembly	1
intracellular protein localization	1
protein transport	1
intracellular transport	1
organelle disassembly	1
viral process	1
viral translation	1
peptidyltransferase activity	1
translational elongation	1
translational termination	1
macromolecule biosynthetic process	1
protein metabolic process	1
protein biosynthetic process	1
formation of translation initiation ternary complex	1
translation	1
metabolic process	1
cellular component organization	1
nucleic acid binding	1
translation factor activity	1
molecular transducer activity	1
intracellular anatomical structure	1
cytoplasm	1
nucleoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1140 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EIF2D	EIF1	P41567	974
EIF2D	DENR	O43583	884
EIF2D	EIF5B	O60841	813
EIF2D	EIF5	P55010	720
EIF2D	ABCE1	P61221	715
EIF2D	EIF3J	O75822	585
EIF2D	EIF4A1	P04765	543
EIF2D	EIF4A2	Q14240	519
EIF2D	RPS25	P25111	505
EIF2D	EIF4G1	Q04637	488
EIF2D	EIF4B	P23588	481
EIF2D	MCTS1	Q9ULC4	469
EIF2D	MRRF	Q96E11	455
EIF2D	EIF4H	Q15056	449
EIF2D	EIF3B	P55884	437

IntAct

29 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
PSMC3	PSMD12	psi-mi:“MI:0914”(association)	0.640
DDX21	MED19	psi-mi:“MI:2364”(proximity)	0.480
EIF2D	HSPA8	psi-mi:“MI:0915”(physical association)	0.400
MKI67	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
PSMC3		psi-mi:“MI:0914”(association)	0.350
	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
CSNK2A1	RPS3A	psi-mi:“MI:0914”(association)	0.350
DNAJC18	PAPSS2	psi-mi:“MI:0914”(association)	0.350
EIF3G	EIF3CL	psi-mi:“MI:0914”(association)	0.350
PSPC1	MCRIP1	psi-mi:“MI:0914”(association)	0.350
RACK1	RPS3A	psi-mi:“MI:0914”(association)	0.350
RPS11	SCAMP1	psi-mi:“MI:0914”(association)	0.350
RPS16	MCRIP1	psi-mi:“MI:0914”(association)	0.350
C11orf87	KLRG2	psi-mi:“MI:0914”(association)	0.350
SLC22A4	RTL8C	psi-mi:“MI:0914”(association)	0.350
PRPS2	SMCHD1	psi-mi:“MI:0914”(association)	0.350
GMPPB	PRMT3	psi-mi:“MI:0914”(association)	0.350
CDC5L		psi-mi:“MI:0914”(association)	0.350
EFTUD2	NACA	psi-mi:“MI:2364”(proximity)	0.270
SBDS	RPSA2	psi-mi:“MI:2364”(proximity)	0.270
ZC3H11A	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
ZNF800	MED19	psi-mi:“MI:2364”(proximity)	0.270
DDX6	RPSA2	psi-mi:“MI:2364”(proximity)	0.270
EIF2D	RAD51	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (71): EIF2D (Affinity Capture-MS), EIF2D (Affinity Capture-MS), CALU (Co-fractionation), CKAP5 (Co-fractionation), EIF1 (Co-fractionation), EIF2D (Co-fractionation), EIF2D (Co-fractionation), EIF2D (Co-fractionation), EIF2D (Co-fractionation), EIF2D (Co-fractionation), EIF2D (Co-fractionation), HARS (Co-fractionation), HNRNPR (Co-fractionation), NAA38 (Co-fractionation), RCC2 (Co-fractionation)

ESM2 similar proteins: A0A1L1SUL6, F1LQY6, O35465, O43379, O75293, O88910, O88954, P0C0T1, P21964, P22339, P41214, P50747, Q13368, Q13572, Q14318, Q16342, Q1HAQ0, Q28955, Q2T9Z1, Q3B7U9, Q3TFD2, Q3TMX7, Q496Y0, Q4AC99, Q5BIM1, Q5E9A5, Q5R812, Q5RA63, Q5SZD4, Q64311, Q6DC64, Q6P5G6, Q6PFY8, Q80YV4, Q8BNV1, Q8BYN3, Q8NFZ0, Q8R1C6, Q8R1T1, Q8TCU6

Diamond homologs: P0CL18, P41214, P87313, Q58CR3, Q5PPG7, Q5RA63, Q61211, A0A3B3IRV3, P89886, Q2KIE4, Q4G009, Q58827, Q5PPY1, Q5ZI42, Q6DER1, Q6NRJ7, Q75AA8, Q7ZV34, Q86KL4, Q9CQ21, Q9DB27, Q9ULC4, Q9W445

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 41 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of expression of SLITs and ROBOs	5	11.9×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	5	24.4×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

124 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	91
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2515 predictions. Top by Δscore:

Variant	Effect	Δscore
1:206583257:T:TA	acceptor_gain	1.0000
1:206583265:CCAG:C	acceptor_loss	1.0000
1:206583266:CA:C	acceptor_loss	1.0000
1:206583267:A:AG	acceptor_gain	1.0000
1:206583267:AGAAT:A	acceptor_gain	1.0000
1:206583268:G:GG	acceptor_gain	1.0000
1:206583268:GA:G	acceptor_gain	1.0000
1:206583268:GAA:G	acceptor_gain	1.0000
1:206583268:GAAT:G	acceptor_gain	1.0000
1:206583268:GAATG:G	acceptor_gain	1.0000
1:206583375:AACTG:A	donor_gain	1.0000
1:206583376:ACTG:A	donor_gain	1.0000
1:206583376:ACTGG:A	donor_loss	1.0000
1:206583377:CTG:C	donor_gain	1.0000
1:206583378:TG:T	donor_gain	1.0000
1:206583378:TGG:T	donor_loss	1.0000
1:206583379:GG:G	donor_gain	1.0000
1:206583379:GGTAA:G	donor_loss	1.0000
1:206583380:G:GG	donor_gain	1.0000
1:206584681:CAAGG:C	donor_loss	1.0000
1:206584682:AAGG:A	donor_loss	1.0000
1:206584684:GGTAG:G	donor_loss	1.0000
1:206584685:G:A	donor_loss	1.0000
1:206584686:T:G	donor_loss	1.0000
1:206585178:A:AG	acceptor_gain	1.0000
1:206585179:G:GG	acceptor_gain	1.0000
1:206585179:GT:G	acceptor_gain	1.0000
1:206586802:A:AG	acceptor_gain	1.0000
1:206586803:C:G	acceptor_gain	1.0000
1:206586804:A:AG	acceptor_gain	1.0000

AlphaMissense

3812 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:206600281:C:A	K310N	0.993
1:206600281:C:G	K310N	0.993
1:206611371:T:A	R20S	0.993
1:206611371:T:G	R20S	0.993
1:206593783:A:T	V507D	0.991
1:206611372:C:G	R20T	0.989
1:206605497:C:G	A145P	0.988
1:206609448:A:G	W87R	0.988
1:206609448:A:T	W87R	0.988
1:206599823:A:G	L321P	0.987
1:206611366:A:G	L22P	0.987
1:206605410:C:G	D174H	0.986
1:206605496:G:T	A145D	0.986
1:206612337:A:C	F2L	0.986
1:206612337:A:T	F2L	0.986
1:206612339:A:G	F2L	0.986
1:206599505:A:T	V387D	0.983
1:206600283:T:C	K310E	0.983
1:206608323:A:G	L112S	0.983
1:206612298:C:A	K15N	0.983
1:206612298:C:G	K15N	0.983
1:206605401:A:G	W177R	0.982
1:206605401:A:T	W177R	0.982
1:206602368:G:C	S290R	0.981
1:206602368:G:T	S290R	0.981
1:206602370:T:G	S290R	0.981
1:206605490:C:T	G147E	0.981
1:206605436:C:T	G165D	0.980
1:206597190:A:T	V433E	0.979
1:206611186:G:T	T82K	0.979

dbSNP variants (sampled 300 via entrez): RS1000085991 (1:206577586 C>T), RS1000146813 (1:206576059 G>A), RS1000184971 (1:206570988 T>A), RS1000261220 (1:206613354 G>A,C,T), RS1000315833 (1:206607032 T>C), RS1000371563 (1:206607295 C>T), RS1000541046 (1:206577378 T>C), RS1000629849 (1:206614368 A>C,G), RS1000696574 (1:206612746 T>A,C), RS1000704584 (1:206608797 A>C), RS1000991337 (1:206602659 C>T), RS1001040682 (1:206595523 G>A), RS1001230082 (1:206583929 G>A), RS1001255915 (1:206577989 G>A), RS1001307830 (1:206571703 G>A)

Disease associations

OMIM: gene MIM:613709 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010121_3	Ceramide levels (C24:0)	9.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, affects binding, decreases reaction, increases reaction, decreases expression	4
Valproic Acid	affects expression, decreases expression	4
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	2
Acrolein	affects cotreatment, increases oxidation, increases abundance	2
Ozone	affects cotreatment, increases oxidation, increases abundance	2
aristolochic acid I	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
bisphenol A	affects expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
perfluorooctane sulfonic acid	increases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Arsenic	decreases expression, increases abundance	1
Cisplatin	affects cotreatment, increases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ribonucleotides	affects binding, decreases reaction	1
Rotenone	decreases expression	1
Smoke	decreases expression	1
Tretinoin	decreases expression	1
Aflatoxin B1	decreases methylation	1
Okadaic Acid	decreases expression	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

Cellosaurus cell lines

5 cell lines: 4 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2WE	Abcam HEK293T EIF2D KO	Transformed cell line	Female
CVCL_SL72	HAP1 EIF2D (-) 1	Cancer cell line	Male
CVCL_SL73	HAP1 EIF2D (-) 2	Cancer cell line	Male
CVCL_SL74	HAP1 EIF2D (-) 3	Cancer cell line	Male
CVCL_SL75	HAP1 EIF2D (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.